Please ensure Javascript is enabled for purposes of website accessibility

Alere Inc. Has Been Left for Dead, With Its Shares Down 13%

By Sean Williams - Nov 4, 2016 at 3:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Poor Q3 results combined with allegations of submitting claims for deceased patients equals a bad day.

Image source: Getty Images.

What happened

Shares of Alere (NYSE: ALR), a provider of diagnostic tests to the medical community for disease detection, plunged as much as 16% during Friday's trading session after releasing disappointing third-quarter earnings results, and announcing that one of its business units has had its Medicare status revoked.

So what

For the quarter, Alere reported revenue of $582 million, a 4% decline from the prior-year quarter, despite 11% growth from its infectious-disease diagnostics. Revenue for the company's cardiometabolic diagnostic tests, which are its largest platform by sales, declined 10% in Q3. Net income from operations totaled $0.46 per share on an adjusted basis, which was shy of the $0.54 consensus estimate on Wall Street, with adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $63.6 million. Alere has now missed Wall Street's profit expectations in four of the past five quarters.

Perhaps more worrisome was the disclosure that the Centers for Medicare and Medicaid Services had revoked the Medicare status of the company's Arriva Medical unit after claims were filed for 211 deceased patients over a five-year period. According to Alere, only 47 of those claims were specifically identified, and Alere made clear that these 211 claims are out of a pool of 5.8 million claims made over that time period. Alere also suggests that it did not receive reimbursement from the aforementioned 211 claims. Alere hopes to have its Medicare status reinstated retroactively, but there are no guarantees that'll happen.

Image source: Getty Images.

Now what

Alere has been a mess for months. After delaying the filing of its annual report by more than four months, the company finally submitted partial results in mid-July to the Securities and Exchange Commission. The delay stemmed from improper revenue recognition that went on for a period of three years. Allegedly, the company was recognizing revenue when products were shipped to distributors, rather than when they were paid for.

Making matters even stranger, Abbott Laboratories (ABT 1.70%) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. Abbott has seemed more than willing to back out of the deal and pay Alere an associated breakup fee, but Alere's management team has clung to Abbott's offer with a viselike grip. In fact, Alere has sued Abbott to essentially force the company to complete the merger. It's really an odd situation.

Given the company's relatively weak third-quarter report, the revoking of its Medicare status for Arriva, its internal control issues with accounting, and the ongoing brouhaha between it and its potential acquirer Abbott, I believe the only true recourse here is to stay as far away from Alere as possible.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$115.11 (1.70%) $1.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.